论文部分内容阅读
目的 探讨 2 8例肝炎后肝硬化 ,在综合治疗的基础上 ,加用前列腺素E1的疗效及不良反应。方法 采用治疗组 (2 8例 )与对照组 (2 5例 )的方法 ,对照组采用综合治疗 ,治疗组在综合治疗的基础上加用前列腺素E1。结果 治疗组病死率为 2 1 4% ,明显低于对照组 (40 % ) ,总有效率治疗组 (78 6 % )明显优于对照组 (6 0 % ) (P <0 0 5 ) ,未见严重不良反应。结论 前列腺素E1治疗肝炎后肝硬化 ,安全可靠 ,效果好 ,值得临床推广使用。
Objective To investigate the post-hepatitis cirrhosis (28 cases). On the basis of comprehensive treatment, the efficacy and adverse reactions of prostaglandin E1 were added. Methods The treatment group (28 cases) and the control group (25 cases) were used in the control group. The treatment group was treated with prostaglandin E1 on the basis of comprehensive treatment. Results The mortality in treatment group was 21.4%, significantly lower than that in control group (40%). The total effective rate in treatment group (78.6%) was significantly better than that in control group (60%) (P <0 05) See serious adverse reactions. Conclusions Prostaglandin E1 is safe, reliable and effective in the treatment of posthepatitic cirrhosis. It is worthy of clinical application.